UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of **November 2026**

Commission File Number: **001-36187**

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

Quarterly Results of Operations

On November 19, 2026, Evogene Ltd. ("**Evogene**") announced its financial results for the third quarter and nine months ended September 30, 2026. A copy of the press release announcing those results is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this "**Form 6-K**") and is incorporated herein by reference.

Evogene is holding a conference call on November 19, 2026 to discuss its quarterly results for the quarter ended September 30, 2026 and, in connection with that call, will make available to its investors a slide presentation to provide additional information regarding its business and its financial results. That slide presentation is attached as Exhibit 99.2 to this Form 6-K and is incorporated herein by reference.

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release dated November 19, 2026, titled "Evogene Reports Financial Results for the Third Quarter and First Nine Months of 2026."
99.2	Slide presentation for the conference call of Evogene held on November 19, 2026, discussing Evogene's financial results for the third quarter of 2026.

Incorporation by Reference

The consolidated financial statements tables contained in Exhibit 99.1 to this Form 6-K, which have been prepared in accordance with International Financial Reporting Standards, are incorporated by reference into the registration statements on Form F-3 (**SEC** File Nos. 333-277565 and 333-294650) and Form S-8 (SEC File Nos. 333-193788, 333-201443, 333-203856, 333-259215, 333-286197 and 333-294648) of Evogene, and shall be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD.
(Registrant)

Date: November 19, 2026

By: /s/ Ofer Haviv
Ofer Haviv
Chief Executive Officer

Exhibit 99.1

Evogene Reports Financial Results for the Third Quarter and First Nine Months of 2026, Highlighting Progress in Two Internal Development Programs

Company advances its internally developed drug discovery program targeting acute graft-versus-host disease (aGVHD) and AgPlenus' fungicide discovery programs targeting novel MoA against Septoria

Rehovot, Israel – November 19, 2026 - Evogene Ltd. (Nasdaq: EVGN; TASE: EVGN), a computational chemistry company leveraging proprietary AI-driven technologies to design and develop novel small molecules for the pharmaceutical and agricultural industries, today reported its financial results for the third quarter and first nine months of 2026, and provided an update on its business activities.

Ofer Haviv, Evogene's President and CEO, stated: "During the third quarter, we continued to advance our strategy of leveraging our proprietary AI-driven discovery platform, ChemPass AI™, to develop innovative small-molecule-based products with significant commercial potential. Alongside our collaborative discovery activities, we are advancing two internal development programs that represent an important component of our strategy to build a pipeline of proprietary assets fully owned and managed by Evogene.

The first one is our internal drug discovery program targeting acute graft-versus-host disease (aGVHD), a serious medical condition associated with significant unmet medical need. Within just several months, Using ChemPass AI™, we generated a series of novel, small-molecule candidates, that demonstrated biological potency, at nanomolar concentrations, as well as encouraging preliminary ADME and toxicology profiles. We are now focused on further optimizing these molecules, identifying the most promising candidates, and advancing the program toward IND-enabling studies. (*For more information, please see our PR from 28, October 2026*)

The second program, conducted through our subsidiary AgPlenus, focuses on discovering fungicides with new modes of action targeting Septoria tritici blotch, a major wheat disease for which resistance to existing fungicides is a growing challenge. Using ChemPass AI for Ag™, AgPlenus identified compounds that showed promising activity against fungicide-resistant Septoria strains. Selected compounds also reduced disease severity by up to 75%, compared to untreated controls, in plant tissue assays and demonstrating activity against additional fungal pathogens, indicating broader fungicidal potential. (*For more information, please see our PR from 17, November 2026*)

The progresses achieved across these initiatives demonstrates the ability of ChemPass AI™ and ChemPass AI for Ag™ to translate computational discovery into experimentally validated molecules exhibiting promising biological activity. More importantly, these programs reflect our strategic focus on converting technological capabilities into differentiated, proprietary product candidates offering meaningful commercial potential, ultimately creating long-term value for Evogene and its shareholders. "

Financial Results and Analysis

Cash Position

As of September 30, 2026, Evogene held consolidated cash, cash equivalents and short-term bank deposits of approximately $9.2 million. Consolidated cash usage during the third quarter of 2026 was approximately $2.4 million, including a Directors' and Officers' insurance payment of approximately $0.5 million, covering an 18-month period.

Revenues

Revenues for the nine months of 2026 totaled approximately $0.8 million, compared to approximately $3.2 million in the same period of 2025, representing a decrease of approximately $2.4 million. The decrease is mainly attributable to lower revenue recognized by Casterra, which in the first half of 2025 included significant seed sales of approximately $2.0 million. Revenues for the third quarter of 2026 were approximately $0.1 million compared to approximately $0.3 million in the third quarter of 2025, mainly due to the conclusion of the license and collaboration agreement with Bayer in May 2026.

Research and Development Expenses

Research and development expenses, net of non-refundable grants, for the nine months of 2026 were approximately $4.5 million, compared to approximately $4.6 million in the corresponding period of 2025, representing a decrease of approximately $0.1 million. For the third quarter of 2026, R&D expenses were approximately $1.5 million, an increase from $1.1 million in the same period of 2025. The increase was mainly attributable to the recognition of a non-refundable grant of approximately $0.2 million and an adjustment to liabilities in respect of government grants of approximately $0.1 million, both of which reduced R&D expenses in the third quarter of 2025, as well as the impact of fluctuations in the USD/NIS exchange rate, between the periods.

Sales and Marketing Expenses

Sales and marketing expenses for the nine months of 2026 were approximately $0.9 million, compared to approximately $1.1 million in the corresponding period of 2025. Sales and marketing expenses for the third quarter of 2026 were approximately $0.2 million, compared to approximately $0.4 million in the third quarter of 2025, primarily due to lower sales and marketing expenses at Casterra and AgPlenus.

General and Administrative Expenses

General and administrative expenses for the nine months ended September 30, 2026, decreased slightly to approximately $3.1 million, compared to approximately $3.2 million in the corresponding period of 2025. For the third quarter of 2026, general and administrative expenses were approximately $1.1 million, remaining relatively unchanged compared to the same period of 2025. The decrease in general and administrative expenses across Evogene and its subsidiaries was largely offset, mainly by transaction costs associated with the warrant inducement transaction and additional non-recurring legal expenses related to corporate governance and shareholders matters. These costs totaled approximately $0.4 million and $0.3 million during the nine-month and three-month periods ended September 30, 2026, respectively.

Financing Expenses (Income), Net

Financing expenses, net, for the nine months of 2026 were approximately $1.6 million, compared to financing income, net, of approximately $0.9 million in the corresponding period of 2025. This change was primarily related to the accounting treatment and revaluation of warrants, including warrants issued in the August 2024 financing and the February 2026 warrant inducement transaction. As part of the February 2026 warrant inducement transaction, the Company recorded financing expenses of approximately $3.8 million during the first nine months of 2026. In addition, the Company recorded financing income of approximately $2.3 million related to the revaluation of warrants liability as of September 30, 2026. For the third quarter of 2026, financing income, net, was approximately $176 thousand, compared to approximately $79 thousand in the corresponding period of 2025, with no material change between the periods.

Loss from Discontinued Operations

Loss from discontinued operations, net, for the nine months of 2026 was approximately $0.5 million, compared to an income from discontinued operations, net, of approximately $4.0 million in the corresponding period of 2025. For the third quarter of 2026, the loss from discontinued operations was approximately $0.06 million, compared to income of approximately $7.6 million in the third quarter of the previous year. These amounts primarily reflect the financial results of Lavie Bio's and Biomica's operations, as well as expenses related to the development and maintenance of MicroBoost AI for Ag, which are presented as a single-line item in the consolidated statements of profit and loss. Following the sale of the majority of Lavie Bio's assets, as well as Evogene's MicroBoost AI for Ag, to ICL in July 2025 and the licensing agreement with Lishan in February 2026, Lavie Bio's and Biomica's operating expense levels have decreased significantly. Biomica's operations were classified as discontinued operations beginning in the second quarter of 2026, and accordingly, the 2025 comparative figures have been reclassified to conform to the current period presentation. Lavie Bio's operations, as well as expenses related to the development and maintenance of MicroBoost AI for Ag, had already been classified as discontinued operations in 2025.

Net Loss

Net loss for the nine months ended September 30, 2026, was approximately $10.5 million, compared to approximately $2.5 million in the corresponding period of 2025. The $8.0 million increase in net loss was primarily attributable to lower revenues, higher financing expenses, and income recognized in connection with the ICL transaction during the corresponding period of 2025. For the third quarter of 2026, net loss was approximately $2.9 million, compared to net income of approximately $5.2 million in the same period of 2025. The change was primarily attributable to income recognized in connection with the ICL transaction during the third quarter of 2025, as discussed above.

About Evogene Ltd.

Evogene Ltd. (Nasdaq/TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for drug development and ag chemical products. At the core of its technology is *ChemPass AI*^{TM}, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.

For more information, please visit www.evogene.com.

About AgPlenus Ltd.

AgPlenus, a subsidiary of Evogene Ltd., is an AI-driven crop protection discovery company focused on developing effective and sustainable solutions to address the growing challenge of pesticide resistance. The company leverages ChemPass AI for Ag™, a technology platform licensed from Evogene, integrating predictive biology, artificial intelligence, and computational chemistry to discover novel crop-protection molecules. Through its target-based discovery approach, AgPlenus aims to improve discovery efficiency, reduce development risks, and advance differentiated crop-protection solutions with the potential to address unmet agricultural needs.

For more information, please visit www.agplenus.com

Forward-Looking Statements

This press release *contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may," "could," "expects," "hopes," "intends," "anticipates," "plans," "believes," "scheduled," "estimates," "demonstrates" or words of similar meaning. For example, Evogene uses forward-looking statements in this press release when it discusses, among other things: its advancing its existing pharmaceutical and agricultural division programs toward subsequent stages of development; its potential, future revenue generation as its pharmaceutical programs progress through development and toward commercialization; its potential establishment of additional collaborations with leading biotechnology and pharmaceutical companies; its advancement of its internal high-value programs, including its internal drug discovery program under which proprietary molecules have the potential to serve as candidates for future preclinical development; its discovery program for new fungicides via AgPlenus; pursuit of strategic partnerships in agriculture; its continuing to strengthen its computational platform; and its ability to execute its strategy and create long-term shareholder value.*

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene, including: the aftermath of the recent wars between Israel and the United States, on the one hand, and Iran and its proxy terrorist groups*, Hamas, Hezbollah, and, intermittently, the Houthis in Yemen, on the other hand, (and any destabilizations in Israel, neighboring territories or the Middle East region resulting from those wars; Evogene's and its subsidiaries' reliance on third parties to conduct certain activities, such as field-trials and pre-clinical studies, which could cause significant delays in the conduct of those activities; the potential impact of a change of control of Evogene's board of directors due to the actions of dissident shareholders; as well as those additional risk factors identified in Evogene's reports filed with the applicable securities authority. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Evogene's actual results to differ from those reflected in its forward-looking statements, please see "Item 3.D. Risk Factors" in Evogene's Annual Report on Form 20-F for the year ended December 31, 2025, and its subsequent reports filed with or furnished to the U.S. Securities and Exchange Commission and Israeli Securities Authority. You should not place undue reliance on any forward-looking statements included in this press release. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions, except to the extent required by applicable law.*

Investor Relations Contact:

ir@evogene.com
Tel: +972-8-9311901

CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

U.S. dollars in thousands

	September 30, 2026	December 31, 2025
	Unaudited	
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	$ 8,571	$ 12,956
Restricted cash	33	32
Short-term bank deposits	655	-
Trade receivables	232	317
Other receivables and prepaid expenses	1,181	1,565
Deferred expenses related to issuance of warrants	-	551
Inventories	65	210
	10,737	15,631
LONG-TERM ASSETS:		
Long-term deposits and other receivables	5	571
Investment accounted for using the equity method	-	43
Deferred expenses related to issuance of warrants	-	1,165
Right-of-use-assets	1,446	1,824
Property, plant and equipment, net	446	812
	1,897	4,415
TOTAL ASSETS	$ 12,634	$ 20,046
LIABILITIES AND EQUITY		
CURRENT LIABILITIES:		
Trade payables	$ 593	$ 639
Employees and payroll accruals	703	861
Lease liabilities	618	716
Liabilities in respect of government grants	142	56
Deferred revenues and other advances	21	17
Warrants and pre-funded warrants liability	496	706
Other payables	389	449
	2,962	3,444
LONG-TERM LIABILITIES:		
Lease liabilities	1,287	1,482
Liabilities in respect of government grants	3,082	3,073
Deferred revenues and other advances	60	72
	4,429	4,627
TOTAL LIABILITIES	$ 7,391	$ 8,071

CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

U.S. dollars in thousands

SHAREHOLDERS' EQUITY:		
Ordinary shares of NIS 0.2 par value: Authorized - 30,000,000 ordinary shares; Issued and outstanding – 18,052,405 ordinary shares on September 30, 2026 and 8,718,193 ordinary shares on December 31, 2025	1,103	488
Share premium and other capital reserves	288,212	281,986
Accumulated deficit	(293,043)	(282,556)
Equity attributable to equity holders of the Company	(3,728)	(82)
Non-controlling interests	8,971	12,057
TOTAL EQUITY	5,243	11,975
TOTAL LIABILITIES AND EQUITY	$ 12,634	$ 20,046

CONSOLIDATED INTERIM STATEMENTS OF PROFIT OR LOSS

U.S. dollars in thousands (except share and per share amounts)

	Nine months ended September 30,		Three months ended September 30,		Year ended December 31,
	2026	2025(*)	2026	2025(*)	2025(*)
	Unaudited				Audited
Revenues	$ 822	$ 3,189	$ 141	$ 312	$ 3,503
Cost of revenues:					
Inventory impairment	-	-	-	-	2,180
Other cost of revenues	428	1,810	92	157	1,914
Total Cost of Revenues	428	1,810	92	157	4,094
Gross profit	394	1,379	49	155	(591)
Operating expenses:					
Research and development, net	4,466	4,635	1,528	1,133	6,262
Sales and marketing	908	1,061	200	358	1,359
General and administrative	3,096	3,154	1,112	1,091	4,021
Other expenses (income)	293	(191)	191	-	(205)
Total operating expenses, net	8,763	8,659	3,031	2,582	11,437
Operating loss	(8,369)	(7,280)	(2,982)	(2,427)	(12,028)
Financing income	2,559	2,352	255	513	2,618
Financing expenses	(4,124)	(1,445)	(79)	(434)	(1,841)
Financing income (expenses), net	(1,565)	907	176	79	777
Share of loss from equity accounted investment	(43)	(82)	-	(16)	(39)
Loss before taxes on income	(9,977)	(6,455)	(2,806)	(2,364)	(11,290)
Taxes on income (tax benefit)	-	1	-	-	1
Loss from continuing operations	(9,977)	(6,456)	(2,806)	(2,364)	(11,291)
Income (loss) from discontinued operations, net	(548)	3,983	(56)	7,561	3,464
Net income (loss)	$ (10,525)	$ (2,473)	$ (2,862)	$ 5,197	$ (7,827)
Attributable to:					
Equity holders of the Company	$ (10,487)	$ (3,176)	$ (2,849)	$ 3,874	(8,485)
Non-controlling interests	(38)	703	(13)	1,323	658
	$ (10,525)	$ (2,473)	$ (2,862)	$ 5,197	$ (7,827)
Basic and diluted loss per share from continuing operations, attributable to equity holders of the Company	$ (0.75)	$ (0.84)	$ (0.17)	$ (0.27)	$ (1.41)
Basic and diluted loss per share from discontinued operations, attributable to equity holders of the Company	$ (0.04)	$ 0.42	$ (0.00)	$ 0.71	$ 0.33
Weighted average number of shares used in computing basic and diluted loss per share	13,245,869	7,588,486	16,894,446	8,716,424	7,874,039

(*) Reclassified to conform to the current period presentation, following the classification of certain operations as discontinued operations.

CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

	Nine months ended September 30,		Three months ended September 30,		Year ended December 31,
	2026	2025(*)	2026	2025(*)	2025(*)
	Unaudited				Audited
Cash flows from operating activities					
Loss from continuing operations	$ (9,977)	$ (6,456)	$ (2,806)	$ (2,364)	$ (11,291)
Adjustments to reconcile loss to net cash used in operating activities:					
Adjustments to the profit or loss items:					
Depreciation of property, plant and equipment and right-of-use-assets	501	748	167	241	971
Impairment of Property, Plant and Equipment	116	-	-	-	-
Inventory impairment	-	-	-	-	2,180
Share-based compensation	80	570	(13)	125	728
Remeasurement of Convertible SAFE	-	(371)	-	(26)	(371)
Net financing expenses (income)	(73)	21	(81)	(135)	(28)
Loss (gain) from sale of property, plant and equipment	(17)	(192)	(3)	2	(205)
Revaluation of government grants	27	24	18	24	40
Amortization of deferred expenses related to issuance of warrants	1,716	989	-	333	1,323
Remeasurement of pre-funded warrants and warrants	(2,271)	(1,664)	(163)	(346)	(1,781)
Expenses related to warrants inducement transaction	2,095	-	-	-	-
Share of loss of an associate	43	82	-	15	39
Allowance for doubtful accounts	78	-	78	-	-
Investment in sub-lease	194	-	194	-	-
Taxes on income (tax benefit)	-	1	-	-	(6)
	2,489	208	197	233	2,890
Changes in asset and liability items:					
Decrease in trade receivables	7	667	74	730	665
Decrease (increase) in other receivables and prepaid expenses	(114)	870	(388)	(417)	958
Decrease (increase) in inventories	145	(740)	28	(139)	(1,019)
Increase (decrease) in trade payables	62	(195)	187	(31)	(40)
Decrease in employees and payroll accruals	(143)	(335)	(204)	(226)	(494)
Increase (decrease) in other payables	16	(343)	117	(45)	(344)
Decrease in deferred revenues and other advances	(8)	(356)	(5)	(5)	(361)
	(35)	(432)	(191)	(133)	(635)

(*) Reclassified to conform to the current period presentation, following the classification of certain operations as discontinued operations.

CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

	Nine months ended September 30,		Three months ended September 30,		Year ended December 31,
	2026	2025(*)	2026	2025(*)	2025(*)
	Unaudited				Audited
Cash received (paid) during the period for:					
Interest received	246	221	46	45	338
Interest paid	(104)	(221)	(20)	(70)	(256)
Taxes paid	(5)	(11)	-	-	(11)
Net cash used in continuing operating activities	(7,386)	(6,691)	(2,774)	(2,289)	(8,965)
Net cash provided by (used in) discontinued operations activities	(287)	(4,125)	13	(1,044)	(4,537)
Net cash used in operating activities	$ (7,673)	$ (10,816)	$ (2,761)	$ (3,333)	$ (13,502)
Cash flows from investing activities:					
Purchase of property, plant and equipment	$ (13)	(129)	(2)	(7)	$ (199)
Proceeds from sale of property, plant and equipment	115	10	3	10	78
Proceeds from finance sub-lease asset	17	29	-	12	52
Investment in bank deposits, net	(655)	(3,700)	(655)	(2,699)	(1)
Net cash provided by (used in) continuing investing activities	(536)	(3,790)	(654)	(2,684)	(70)
Net cash provided by (used in) discontinued investing activities	483	11,265	483	13,593	17,808
Net cash provided by (used in) investing activities	$ (53)	$ 7,475	$ (171)	$ 10,909	$ 17,738

(*) Reclassified to conform to the current period presentation, following the classification of certain operations as discontinued operations.

CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

	Nine months ended September 30,		Three months ended September 30,		Year ended December 31,
	2026	2025(*)	2026	2025(*)	2025(*)
	Unaudited				Audited
Cash flows from financing activities:					
Proceeds from issuance of ordinary shares, net of issuance expenses	3,155	4,283	2,350	-	4,283
Proceeds from issuance of ordinary shares in warrant inducement transaction, net of issuance expenses	3,206	-	-	-	-
Repayment of lease liability	(334)	(315)	(121)	(87)	(423)
Dividend paid by subsidiary	(2,672)	-	-	-	-
Repayment of convertible SAFE	-	(10,000)	-	(10,000)	(10,000)
Proceeds from government grants	101	-	-	-	-
Repayment of government grants	(34)	(122)	(14)	-	(244)
Net cash provided by (used in) continuing financing activities	3,422	(6,154)	2,215	(10,087)	(6,384)
Net cash used in discontinued financing activities	(80)	(192)	(30)	(249)	(218)
Net cash provided by (used in) financing activities	$ 3,342	$ (6,346)	$ 2,185	$ (10,336)	$ (6,602)
Exchange rate differences - cash and cash equivalent balances	(1)	12	2	(13)	21
Decrease in cash and cash equivalents	(4,385)	(9,675)	(745)	(2,773)	(2,345)
Cash and cash equivalents, beginning of the period	12,956	15,301	9,316	8,329	15,301
Cash and cash equivalents presented in assets held for sale	-	-	-	70	-
Cash and cash equivalents, end of the period	$ 8,571	$ 5,626	$ 8,571	$ 5,626	$ 12,956
Significant non-cash activities					
Acquisition of property, plant and equipment	$ -	$ 2	$ -	$ -	$ 2
Right-of-use asset recognized with corresponding lease liability	$ 33	$ 207	$ -	$ -	$ 207
Exercise of pre-funded warrants	$ -	$ 389	$ -	$ -	$ 389
Derecognition of property, plant and equipment under a finance lease	$ -	$ 13	$ -	$ -	$ 13

(*) Reclassified to conform to the current period presentation, following the classification of certain operations as discontinued operations.

Exhibit 99.2


evogene
REAL-WORLD INNOVATION
EARNINGS CALL
Q3 2026
November 19, 2026

FORWARD LOOKING STATEMENT

This presentation contains 'forward-looking statements" relating to future events, and Evogene Ltd. (the "Company"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws, as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, pipeline, as well as our capabilities and technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation.

Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, the aftermath of the recent war between Israel and each of (i) the terrorist groups, Hamas and Hezbollah, (ii) Iran, and (iii) other regional terrorist groups supported by Iran, and any destabilizations in Israel, neighboring territories or the Middle East region, and those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.



EARNINGS CALL Q3 2026


AGENDA

- CEO Update – By Ofer Haviv
- VP Finance Update – By Polina Ravzin
- Q&A

INTERNALLY DEVELOPED DRUG DISCOVERY PROGRAM

NOVEL SMALL-MOLECULE THERAPIES FOR STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (aGVHD)

- aGVHD is a life-threatening complication of hematopoietic stem cell transplantation, affecting approximately 30%–40% of transplant recipients
- Global GVHD treatment market is estimated at $2B annually, with steroid-refractory aGVHD form estimated market of $0.5B with a strong clinical unmet need
- Target: key cellular protein expressed in a wide range of cell types involved in cell motility, structure and immune regulation
- Combines *ChemPass AI™* novel molecule generation capabilities with program guidance of world-renowned experts in the field



STRUCTURE OF BINDING SITE AND PUTATIVE LIGAND

INTERNALLY DEVELOPED DRUG DISCOVERY PROGRAM FOR AGVHD

EXPERIMENTAL RESULTS

HIT ID - CHEMICAL SPACE DIFFERENTIATION WITH *POINTHIT™* (STEP1)


Identified active candidates represent different chemical space from the known inhibitors

EFFICIENT HIT EXPANSION THROUGH *ACTIVESEARCH™* (STEP2)

Lead candidates show better-than-expected efficiency

NOVEL MOLECULE GENERATION USING LEADOPGPTTM (STEP3)

first batch ordered and awaits experimental validation



Top 5 molecules

Compound	IC50(nM)
CPV110	0.4
CPV128	2.7
CPV161	4.1
CPV138	4.9
CPV205	7.4



Dr. Corey Cutler
Dana-Farber Cancer Institute and HMS



Prof. Dr. Robert Zeiser
University of Freiburg

agPlenus
EVOGENE'S SUBSIDIARY

AGPLENUS SEPTORIA INTERNAL PROGRAM

THE CHALLENGE & NEED

MAJOR WHEAT DISEASE
Leads to major wheat yield losses, ranking 1st in Europe, and 2nd in the US

MARKET OPPORTUNITY
>70% of fungicide use in Europe. Estimated opportunity: ~€1.2 billion[1].

RISING RESISTANCE
Reduced sensitivity to azoles and SDHIs calls for new modes of action[2]

AGPLENUS STRATEGY

- New fungicide modes of action
- ChemPass AI + experimental discovery
- Optimize potency and plant-tissue efficacy
- Target resistant strains and other pathogens




[1] Hehir et al. (2018). Plant Pathology, 67, 573–583. DOI
[2] Andresen et al. (2026). European Journal of Plant Pathology. DOI

agPlenus
EVOGENE'S SUBSIDIARY

AGPLENUS SEPTORIA – REPRESENTATIVE RESULTS

AG20133 - COMPOUND PERFORMANCE

TARGET INHIBITION (ENZYME IC_{50} 3 MM)




High protein binding & inhibition

ANTIFUNGAL ACTIVITY (INCLUDING RESISTANT STRAINS)

Pathogen / strain	IC_{50} (µM)
Septoria wild type	**34**
Septoria DMI resistant	33
Septoria SDHI resistant	26
Septoria Qol resistant	33
Other fungal pathogen	35

Results verified by an external research organization

DISEASE REDUCTION



75% Disease inhibition

HARNESSING THE POWER OF CHEMPASS AI FOR REAL-WORLD INNOVATION

PHARMA DIVISION – Drugs

systasy	Neutrophil-Derived Inflammatory Diseases
UNRAVEL BIOSCIENCES	Demyelination Disorders
eleo	Cardiovascular Diseases
QUT Queensland University of Technology	Therapy Resistant Lung Cancer
TEL AVIV UNIVERSITY אוניברסיטת תל אביב	Metabolic Disease
UNDISCLOSED	Oncology Disease
INTERNAL PIPELINE	Acute GVHD

ChemPass AI



AG DIVISION* – Ag-Chemicals

CORTEVA agriscience	Herbicides
INTERNAL PIPELINE	Wheat leaf Blotch (Two targets)
INTERNAL PIPELINE	Undisclosed

AG DIVISION* – Operations in this field are conducted through our subsidiary, AgPlenus.



EARNINGS CALL Q3 2026

AGENDA

- CEO Update – By Ofer Haviv
- VP Finance Update – By Polina Ravzin
- Q&A

VP FINANCE UPDATE

FINANCIAL HIGHLIGHTS

CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

U.S. dollars in thousands

	September 30, 2026 Unaudited	December 31, 2025
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	$ 8,571	$ 12,956
Restricted cash	33	32
Short-term bank deposits	655	-
Trade receivables	232	317
Other receivables and prepaid expenses	1,181	1,565
Deferred expenses related to issuance of warrants	-	551
Inventories	65	210
	10,737	15,631
LONG-TERM ASSETS:		
Long-term deposits and other receivables	5	571
Investment accounted for using the equity method	-	43
Deferred expenses related to issuance of warrants	-	1,165
Right-of-use-assets	1,446	1,824
Property, plant and equipment, net	446	812
	1,897	4,415
TOTAL ASSETS	$ 12,634	$ 20,046
LIABILITIES AND EQUITY		
CURRENT LIABILITIES:		
Trade payables	$ 593	$ 639
Employees and payroll accruals	703	861
Lease liabilities	618	716
Liabilities in respect of government grants	142	56
Deferred revenues and other advances	21	17
Warrants and pre-funded warrants liability	496	706
Other payables	389	449
	2,962	3,444
LONG-TERM LIABILITIES:		
Lease liabilities	1,287	1,482
Liabilities in respect of government grants	3,082	3,073
Deferred revenues and other advances	60	72
	4,429	4,627
TOTAL LIABILITIES	$ 7,391	$ 8,071
SHAREHOLDERS' EQUITY:		
Ordinary shares of NIS 0.2 par value: Authorized – 30,000,000 ordinary shares; Issued and outstanding – 18,052,405 ordinary shares on September 30, 2026 and 8,718,193 ordinary shares on December 31, 2025	1,103	488
Share premium and other capital reserves	288,212	281,986
Accumulated deficit	(293,043)	(282,556)
Equity attributable to equity holders of the Company	(3,728)	(82)
Non-controlling interests	8,971	12,057
TOTAL EQUITY	5,243	11,975
TOTAL LIABILITIES AND EQUITY	$ 12,634	$ 20,046

VP FINANCE UPDATE

FINANCIAL HIGHLIGHTS

CONSOLIDATED INTERIM STATEMENTS OF PROFIT OR LOSS

U.S. dollars in thousands (except share and per share amounts)

	Nine months ended September 30,		Three months ended September 30,		Year ended December 31,
	2026	2025 (*)	2026	2025 (*)	2025 (*)
	Unaudited				Audited
Revenues	$ 822	$ 3,189	$ 141	$ 312	$ 3,503
Cost of revenues:					
Inventory impairment	-	-	-	-	2,180
Other cost of revenues	428	1,810	92	157	1,914
Total Cost of Revenues	428	1,810	92	157	4,094
Gross profit	394	1,379	49	155	(591)
Operating expenses:					
Research and development, net	4,466	4,635	1,528	1,133	6,262
Sales and marketing	908	1,061	200	358	1,359
General and administrative	3,096	3,154	1,112	1,091	4,021
Other expenses (income)	293	(191)	191	-	(205)
Total operating expenses, net	8,763	8,659	3,031	2,582	11,437
Operating loss	(8,369)	(7,280)	(2,982)	(2,427)	(12,028)
Financing income	2,559	2,352	255	513	2,618
Financing expenses	(4,124)	(1,445)	(79)	(434)	(1,841)
Financing income (expenses), net	(1,565)	907	176	79	777
Share of loss from equity accounted investment	(43)	(82)	-	(16)	(39)
Loss before taxes on income	(9,977)	(6,455)	(2,306)	(2,364)	(11,290)
Taxes on income (tax benefit)	-	1	-	-	1
Loss from continuing operations	(9,977)	(6,456)	(2,306)	(2,364)	(11,291)
Income (loss) from discontinued operations, net	(548)	3,983	(56)	7,561	3,464
Net income (loss)	$ (10,525)	$ (2,473)	$ (2,362)	$ 5,197	$ (7,827)

(*) Reclassified to conform to the current period presentation, following the classification of certain operations as discontinued operations.



EARNINGS CALL Q3 2026

AGENDA

- CEO Update – By Ofer Haviv
- VP Finance Update – By Polina Ravzin
- Q&A


evogene
Creating
REAL-WORLD
INNOVATION
for a better future
THANK YOU